Effects of angiotensin converting enzyme inhibitors on thrombotic mediators: potential clinical implications.
Angiotensin-converting enzyme inhibitors (ACE-I) were initially developed as therapeutic agents targeted for the treatment of hypertension. Since the initial application of these agents, several additional clinical indications have been identified such as coronary artery disease, stroke, congestive heart failure and prevention of diabetes-related complications. In addition to the blood pressure lowering effects, this class of agents has the ability to restore endothelial function, decrease oxidative stress and enhance endogenous fibrinolysis. Moreover, ACE-I possesses antiplatelet effects as well as antiproliferatory and antimigratory effects on smooth muscle cells. This article links the effects of ACE-I on thrombotic mediators to the potential clinical implications in the setting of coronary artery disease.
Kothari
Seema A
SA
Saint Vincent Hospital, Massachusetts College of Pharmacy and Health Sciences-Worcester, 19 Foster Street, Worcester, MA 01608, USA.
Le
Mytrang K
MK
Gandhi
Pritesh J
PJ
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D001779:Blood Coagulation Factors / Q000032:analysis / Q000187:drug effects; D001808:Blood Vessels / Q000187:drug effects / Q000473:pathology; D006487:Hemostasis / Q000187:drug effects*; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000473:pathology; D007705:Kinins / Q000187:drug effects / Q000502:physiology; D009203:Myocardial Infarction / Q000188:drug therapy
D000806:Angiotensin-Converting Enzyme Inhibitors; D001779:Blood Coagulation Factors; D007705:Kinins